Literature DB >> 18201277

Portrait of PTEN: messages from mutant mice.

Akira Suzuki1, Toru Nakano, Tak Wah Mak, Takehiko Sasaki.   

Abstract

PTEN is a tumor suppressor gene mutated in many human sporadic cancers and in hereditary cancer syndromes such as Cowden disease. The major substrate of PTEN is phosphatidylinositol-3,4,5-trisphosphate (PI(3,4,5)P3), a second messenger molecule produced following PI3K activation induced by a variety of stimuli. PI(3,4,5)P3 activates the serine-threonine kinase Akt, which is involved in antiapoptosis, proliferation and oncogenesis. In mice, heterozygosity for a null mutation of Pten (Pten(+/-)mice) frequently leads to the development of a variety of cancers and autoimmune disease. Homozygosity for the null mutation (Pten(-/-) mice) results in early embryonic lethality, precluding the functional analysis of Pten in adult tissues and organs. To investigate the physiological functions of Pten in viable mice, we and other groups have used the Cre-loxP system to generate various tissue-specific Pten mutations. The present review will summarize results obtained from the study of conditional mutant mice lacking Pten in specific tissues, and discuss the possible biological and molecular explanations for why Pten deficiency leads to tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18201277     DOI: 10.1111/j.1349-7006.2007.00670.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  41 in total

1.  Shank-interacting protein-like 1 promotes tumorigenesis via PTEN inhibition in human tumor cells.

Authors:  Lizhi He; Alistair Ingram; Adrian P Rybak; Damu Tang
Journal:  J Clin Invest       Date:  2010-05-10       Impact factor: 14.808

Review 2.  MicroRNAs as mediators and therapeutic targets in chronic kidney disease.

Authors:  Johan M Lorenzen; Hermann Haller; Thomas Thum
Journal:  Nat Rev Nephrol       Date:  2011-03-22       Impact factor: 28.314

3.  p85 Associates with unphosphorylated PTEN and the PTEN-associated complex.

Authors:  Rosalia Rabinovsky; Panisa Pochanard; Chontelle McNear; Saskia M Brachmann; Jonathan S Duke-Cohan; Levi A Garraway; William R Sellers
Journal:  Mol Cell Biol       Date:  2009-07-27       Impact factor: 4.272

4.  Molecular regulation of limb growth.

Authors:  Karen Lyons; Marybeth Ezaki
Journal:  J Bone Joint Surg Am       Date:  2009-07       Impact factor: 5.284

Review 5.  PTEN at a glance.

Authors:  Yuji Shi; Benjamin E Paluch; Xinjiang Wang; Xuejun Jiang
Journal:  J Cell Sci       Date:  2012-10-15       Impact factor: 5.285

Review 6.  Phosphatase and tensin homologue deleted on chromosome 10: extending its PTENtacles.

Authors:  Bangyan L Stiles
Journal:  Int J Biochem Cell Biol       Date:  2008-10-02       Impact factor: 5.085

Review 7.  A novel signaling network as a critical rheostat for the biology and maintenance of the normal stem cell and the cancer-initiating cell.

Authors:  Keisuke Ito; Rosa Bernardi; Pier Paolo Pandolfi
Journal:  Curr Opin Genet Dev       Date:  2009-02-11       Impact factor: 5.578

8.  Lin-Sca-1+CD49fhigh stem/progenitors are tumor-initiating cells in the Pten-null prostate cancer model.

Authors:  David J Mulholland; Li Xin; Ashkan Morim; Devon Lawson; Owen Witte; Hong Wu
Journal:  Cancer Res       Date:  2009-11-03       Impact factor: 12.701

9.  Phosphoinositide-dependent kinase 1 controls migration and malignant transformation but not cell growth and proliferation in PTEN-null lymphocytes.

Authors:  David K Finlay; Linda V Sinclair; Carmen Feijoo; Caryll M Waugh; Thijs J Hagenbeek; Hergen Spits; Doreen A Cantrell
Journal:  J Exp Med       Date:  2009-10-05       Impact factor: 14.307

10.  Suppression of cellular proliferation and invasion by the concerted lipid and protein phosphatase activities of PTEN.

Authors:  L Davidson; H Maccario; N M Perera; X Yang; L Spinelli; P Tibarewal; B Glancy; A Gray; C J Weijer; C P Downes; N R Leslie
Journal:  Oncogene       Date:  2009-11-16       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.